Current and Future Management of Hypertrophic Cardiomyopathy with Cardiac Myosin Inhibitors

Cardiac myosin inhibitors have changed the landscape for therapy in patients with obstructive hypertrophic cardiomyopathy. Mavacamten, as the first-in-class cardiac myosin inhibitor is FDA approved to improve exercise capacity and symptoms in adults with NYHA class II-III oHCM. This class of drugs offers an alternative to septal reduction therapies and have been found to be well tolerated when monitored. New trials currently in progress studying the cardiac myosin inhibitors hold promising opportunities to change the hypertrophic cardiomyopathy management landscape.